Conference Coverage

EADV: Ixekizumab promising for psoriatic arthritis

Publish date: October 26, 2015

 

AT THE EADV CONGRESS

References

“Obviously, one needs to look at this more carefully in a phase III psoriatic arthritis study. That’ll provide a more robust answer. But this gives a hint,” the dermatologist said.

The UNCOVER program was sponsored by Eli Lilly. Dr. Gottlieb serves as an adviser to Lilly and numerous other pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

FUTURE 1 trial results fortify evidence base for secukinumab’s efficacy in psoriatic arthritis
MDedge Dermatology
PsA confers higher risk of cardiovascular disease, events
MDedge Dermatology
Psoriasis severity correlates with aortic vascular inflammation
MDedge Dermatology
Combined dermatology-rheumatology clinics improve care, spark new research
MDedge Dermatology
EADV: Long-term weight loss curbs psoriasis severity
MDedge Dermatology
EADV: Latest gruesome twosome: Psoriasis spawns renal disease
MDedge Dermatology
Dactylitis warns of future damage in psoriatic arthritis
MDedge Dermatology
Topical calcipotriene-betamethasone combination approved for plaque psoriasis
MDedge Dermatology
Infections from endemic fungi, mycobacteria rare in patients on TNFIs
MDedge Dermatology
EADV: Investigational biologic rocks psoriasis world
MDedge Dermatology

Related Articles